Ernexa Therapeutics shareholders elect directors, ratify auditor, approve 2026 equity plan

Ernexa Therapeutics Inc.

All five director nominees elected: Bristol, Cicala, Luther, Ratner, Wexler; broker non-votes 161,165.
Ratification of Haskell & White LLP as auditor for FY 2026: 590,236 for, 29,010 against, 495 abstentions.
Approval of 2026 Omnibus Equity Incentive Plan: 363,640 for, 94,840 against, 96 abstentions, 161,165 broker non-votes.
Quorum of 53.13% (619,741 of 1,166,333 shares) represented at the July 1, 2026 annual meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.